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Abstract
Background: Meta-analysis handles randomized trials with no outcome events in both treatment
and control arms inconsistently, including them when risk difference (RD) is the effect measure but
excluding them when relative risk (RR) or odds ratio (OR) are used. This study examined the
influence of such trials on pooled treatment effects.
Methods: Analysis with and without zero total event trials of three illustrative published meta-
analyses with a range of proportions of zero total event trials, treatment effects, and heterogeneity
using inverse variance weighting and random effects that incorporates between-study
heterogeneity.
Results: Including zero total event trials in meta-analyses moves the pooled estimate of treatment
effect closer to nil, decreases its confidence interval and decreases between-study heterogeneity.
For RR and OR, inclusion of such trials causes small changes, even when they comprise the large
majority of included trials. For RD, the changes are more substantial, and in extreme cases can
eliminate a statistically significant effect estimate.
Conclusion: To include all relevant data regardless of effect measure chosen, reviewers should
also include zero total event trials when calculating pooled estimates using OR and RR.
Background
A meta-analysis of randomized controlled trials of a par-
ticular treatment quantitatively synthesizes all available
trial data and provides the least biased estimate of that
treatment's effect. Results from individual studies are sta-
tistically combined to provide a weighted average esti-
mate of overall treatment effect. In one common
weighting scheme known as the inverse variance method,
the treatment effect from each study is weighted by the
inverse of its variance. For binary outcomes, the pooled
effect measure is usually expressed as either a difference of
proportions (risk difference, RD), a ratio of proportions
(relative risk, RR), or a ratio of the odds (odds ratio, OR)
of intervention and control group patients experiencing
an event. The variances of the effect measures for individ-
ual studies are determined by two parameters: the number
of study subjects in each group, and the number of these
subjects with outcome events. Standard meta-analytic
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procedures also produce an estimate of heterogeneity,
which is the extent of variability in treatment effects of
individual trials beyond what would be expected by
chance. For example, I2 is one summary measure of heter-
ogeneity and is the proportion of total variation among
trials due to between-trial variation [1]. Using the inverse
variance method of pooling studies, the weight of each
study can be adjusted in the presence of significant heter-
ogeneity by using the random-effects model [2].
In many studies of patients at low risk of developing the
outcome that the intervention is designed to prevent, no
subjects in either the intervention or the control group, or
both, experience an outcome event. Meta-analyses using
RR or OR as the effect measure traditionally include only
studies with zero events in either the intervention or the
control group, but not both. In contrast, meta-analyses
using RD as the effect measure include studies with zero
events in either or both groups [3,4].
The main argument for excluding zero total event trials
(trials with zero events in both treatment and control
arms) when the pooled effect measure is RR or OR is that
they make no contribution to the magnitude of the treat-
ment effect [5,6]. Although these trials do not contribute
to producing a pooled treatment effect greater or less than
nil, they do provide relevant data by showing that event
rates for both the intervention and control groups are low
and relatively equal [7]. Excluding such trial data poten-
tially creates the risk of inflating the magnitude of the
pooled treatment effect. Indeed, others have argued that
zero total event trials should be included "to take into
account the samples sizes of these studies" [8]. In addi-
tion, some published meta-analyses have included zero
total event trials applying the standard continuity correc-
tion of 0.5 [9], which is commonly used for trials with
zero events in only one arm [10,11]. Others have pro-
posed different continuity corrections that perform better
when the numbers of patients in the intervention and
control groups are severely imbalanced [5].
The continuity correction is added to each cell of a 2 by 2
table for trials with zero events in one or both arms. When
combining such trials using the inverse-variance method,
continuity corrections are required to calculate individual
trial effect estimates and variances (OR and RR) or to cal-
culate individual trial variances (RD). Continuity correc-
tions are less important or not required for other methods
used for fixed effects analyses that do not incorporate
between-study heterogeneity, such as Mantel-Haenszel
methods and Peto OR [3-5]. Continuity corrections are
also not required using Bayesian approaches that incorpo-
rate heterogeneity, although Bayesian methods require
estimates of prior probabilities that are often based on
subjective assessments and opinion [12].
Given these conflicting opinions and practices, the objec-
tive of this study was to examine, using illustrative exam-
ples, the influence of zero total event trials when the
inverse variance method is used to pool RD, RR, and OR
treatment effects.
Methods
We selected 3 illustrative published meta-analyses that
demonstrated a range of proportions of zero total event
trials (among all trials with outcomes data), treatment
effects, and heterogeneity [13-15]. For each binary effect
measure, the meta-analysis was conducted including and
excluding zero total event trials using the inverse variance
random-effects model. For individual trials with no events
in one or both groups, a continuity correction of 0.5 was
added to each cell for each effect measure, as imple-
mented in Review Manager 4.2 [4]. Calculations were car-
ried out using standard equations and confirmed with
Review Manager where possible.
Results
For the meta-analysis of low-dose dopamine [13] (Figure
1), the proportion of zero total event trials is large
(>70%). Given the absence of a significant treatment
effect among trials with at least 1 event, the inclusion of
the zero total event trials decreases the confidence inter-
vals of the pooled effect estimates but not the estimates
themselves. This decrease in confidence interval is greatest
for RD.
For the meta-analysis of antibiotics to prevent rheumatic
fever [14] (Figure 2), the proportion of zero total event tri-
als is smaller but still >50%. Including the zero total event
trials reduces the magnitude of the treatment effect. How-
ever, the smaller treatment effect remains statistically sig-
nificant, in part because of a simultaneous decrease in the
width of the confidence interval resulting from the inclu-
sion of more trials. As with the first example, the reduc-
tion in pooled treatment effect is greatest for RD. In this
example, heterogeneity is either reduced or eliminated for
each of the effect measures.
In the third example (Figure 3) of heparin to prevent non-
fatal pulmonary embolism [15], all trials have at least one
arm with zero events, but only a third are zero total event
trials. In this extreme example, inclusion of the zero total
event trials also decreases the treatment effect for each
pooled effect measure. However, the effect on RD is sub-
stantial and causes the statistical significance (2-sided p <
0.05) of the pooled RD to be lost.
Discussion
Trials in which no patient develops the outcome of inter-
est are conventionally included in estimates of pooled
RD, but not RR and OR. We explored this inconsistencyBMC Medical Research Methodology 2007, 7:5 http://www.biomedcentral.com/1471-2288/7/5
Page 3 of 6
(page number not for citation purposes)
using 3 published meta-analyses and found that when
zero total event trials are included, there is a relatively
small reduction in the magnitude of the pooled RR and
OR and the confidence intervals, resulting in a slightly
more conservative estimate of treatment effect. In con-
trast, for RD where zero total event trials are traditionally
included, the effect is more pronounced, and in 1 extreme
case, inclusion of zero total event trials negated an other-
wise statistically significant treatment effect. Therefore,
excluding zero total event trials could change the clinical
implication of a meta-analysis that used RD exclusively to
pool similarly extreme data.
The greater effect of zero total event trials on RD versus RR
and OR occurs because trials with low event rates have a
much higher weight in the pooled estimate of RD com-
pared to the other measures (graphically depicted in refer-
ence [16]). Because the pooled RR and OR is dominated
by trials with at least 1 event in both groups, it is relatively
insensitive to the inclusion of low-weight zero total event
trials. Even when significant heterogeneity is present,
which increases the relative weighting of low-weighted
zero total event trials in random effects analyses, the
changes in these pooled estimates are still relatively small
(see Figure 2).
We present an extreme example (Figure 3) where the
inclusion of zero total event trials in a meta-analysis using
RD as the effect estimator negates a statistically significant
treatment effect obtained when such trials are excluded.
However, such situations would be expected to occur
rarely because the inclusion of these trials has opposite
impacts on the treatment effect (which becomes closer to
nil) and its confidence interval (which narrows). For RR
and OR, where the changes are smaller, it is even more
unlikely that inclusion of zero total event trials would
negate the statistical significance of a treatment effect,
especially when the meta-analysis contains trials with at
least 1 event in both groups.
The addition of zero total event trials decreased heteroge-
neity in the examples provided. One might have expected
Meta-analysis investigating the use of low-dose dopamine to prevent or treat renal dysfunction [13] Figure 1
Meta-analysis investigating the use of low-dose dopamine to prevent or treat renal dysfunction [13]. Endpoint: mortality (total 
of 109 events in 1523 patients in the intervention group and 105 events in 1454 patients in the control group). The first three 
horizontal bar charts show the proportion of trials, patients, and outcome events in the meta-analysis of all "Trials with No 
Zeros" (trials with at least one event in both the intervention and control arms), "Trials with One Zero" (trials with no events 
in either the intervention or the control arm), and "Trials with Two Zeros" (trials with no events in both the intervention and 
control arms). The next three pairs of bar charts show the total weighting of all trials with no zeros, one zero, and two zeros, 
respectively, in the final pooled RD, OR, and RR. The first bar in each pair refers to a meta-analysis that includes only trials with 
at least one event in either the intervention or the control arm ("Event trials"). The second bar includes both trials with and 
without events ("All trials"). For each effect measure, a corresponding plot indicates the pooled treatment effect estimate with 
its 95% confidence interval (white circles when event trials only are included and black circles when all trials are included), and 
the I2 heterogeneity measure. The RD is plotted on a linear scale, and OR and RR are plotted on the same logarithmic scale. 
Abbreviations: RD = risk difference, OR = odds ratio, RR = relative risk.
DOPAMINE (Mortality)
% Weighting
0 2 04 06 08 0 1 0 0
RR (All trials)
RR (Event trials)
OR (All trials)
OR (Event trials)
RD (All trials)
RD (Event trials)
   
Events (n=214)
Patients (n=2977)
Trials (n=57)
Trials with No Zeros 
Trials with One Zero 
Trials with Two Zeros 
11% 17% 72%
21% 26% 53%
91% 9%
24 76
52 2 73
88 12
68 9 23
95 5
85 4 11
I2
12%
0%
0%
0%
0%
0%
0.6 0.8 1 1.2 1.4 1.6
0.00 0.03 -0.03
Treatment Effect with 95% Confidence IntervalBMC Medical Research Methodology 2007, 7:5 http://www.biomedcentral.com/1471-2288/7/5
Page 4 of 6
(page number not for citation purposes)
that heterogeneity would be increased by adding zero
total event trials to a group of trials, each with at least 1
event, that on average show a non-zero treatment effect.
However, in these examples the treatment effect was sim-
ilar between zero total event trials and event trials. There-
fore, the net effect of including more trials in the meta-
analysis was to reduce heterogeneity. This arises because
the Q statistic, which provides an assessment of heteroge-
neity, has a null Chi-squared distribution with degrees of
freedom equal to one less than the number of trials. If het-
erogeneity increases only slightly as more trials are added,
the increase in Q is small relative to the increased degrees
of freedom and Q is less likely to be statistically signifi-
cant. Similarly the I2 measure of heterogeneity (calculated
as 100%·[Q-degrees of freedom]/Q) decreases. Figure 2
illustrates this effect. Prior to the addition of the zero total
event trials, there is a significant treatment effect and sub-
stantial heterogeneity for each of the effect measures. After
adding the zero event trials, the treatment effect is smaller
but still significant, and the degree of heterogeneity,
expressed as I2, is reduced or eliminated for each of the
effect measures.
For the RD effect measure, the weighting of the zero total
event trials in the pooled result is comparable to the pro-
portion of such trials in the meta-analysis. Therefore,
including a large proportion of zero total event trials with
identical results (i.e. a RD of exactly 0) may result in
reduced heterogeneity by simply overwhelming the other
results even if there is marked heterogeneity among the
remaining trials. Even in the presence of equal underlying
event rates in the treatment and control groups one would
expect some random variation around a RD of 0; however,
zero total event trials are frequently small which makes it
less likely to observe any events in either arm. Thus, these
small underpowered studies contribute to an exaggerated
decrease in heterogeneity. One would expect this to be less
of a factor for OR and RR because the weighting of zero
total event trials in the effect measure is lower, and some-
times significantly lower, than the proportion of such tri-
als included in the meta-analysis (for example see figures
1 and 2).
We used a continuity correction of 0.5 since this is the cor-
rection most commonly used [3,4]. Sweeting et al [5] have
recently proposed two alternative continuity corrections,
one based on the reciprocal of the group (i.e. treatment or
control) size opposite the zero cell, and the second based
on an empirical estimate of the pooled effect size using
the studies in the meta-analysis with events in both the
treatment and control arms. Applying these corrections
instead of 0.5 in two of our examples (dopamine and anti-
biotics to prevent rheumatic fever) gives very similar
results. For the third extreme example (heparin to prevent
non-fatal pulmonary embolism), there are no trials with
events in both the treatment and control groups, prevent-
Meta-analysis investigating the use of antibiotics to treat sore throat [14] Figure 2
Meta-analysis investigating the use of antibiotics to treat sore throat [14]. Endpoint: acute rheumatic fever within 2 months of 
treatment (total of 37 events in 5656 patients in the intervention group and 74 events in 4445 patients in the control group). 
For a description of bar charts and plots see figure legend for Figure 1.
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ing the use of the second alternative correction. Inclusion
of zero total event trials using the continuity correction
based on the reciprocal of the opposite group size negates
a statistically significant treatment effect obtained when
such trials are excluded for all three effect estimators [sim-
ilar to RD in Figure 3, the lower bounds of the 95% confi-
dence interval for the RR and OR effect estimators also
cross unity if this alternative correction is used (results not
shown)]. Using this correction in our case examples
shows that including or excluding zero total event trials
can change the clinical implication of a meta-analysis
pooling similarly extreme data, regardless of the effect
measure used.
We focused on the impact of zero total event trials on
summary effect measures in meta-analyses using inverse
variance weighting, which is the only commonly used
method that can incorporate between-study heterogeneity
in a random effects model. We chose published illustra-
tive meta-analyses that combined high- and low-risk
patients. We did not consider other issues such as the
choice of effect measure, appropriateness of combining
high- and low-risk patients, the choice of a fixed vs. ran-
dom effects model, or other methods for addressing het-
erogeneity.
In contrast to our illustrative examples combining high-
and low-risk patients, two recently published simulation
studies provide comprehensive comparisons of multiple
meta-analytic methods when baseline event rates are low
[5,17]. These studies, both of which excluded zero total
event trials for the OR simulations, suggest that in general
the commonly used continuity correction of 0.5 biases the
Mantel-Haenszel and inverse variance OR estimators
[5,17]. The simulation study that examined RD demon-
strated that when events are rare, using RD widened con-
fidence intervals and thus lowered statistical power
compared to other methods [17]. Finally, although the
inverse variance method is the only non-Bayesian method
that incorporates between-study heterogeneity, the same
authors found that it gives biased effect estimates when
event rates are low. Although this bias is present at mod-
erate event rates and effect sizes, it becomes greater than
1% when event rates are very low (± 1%) or treatment
effects very large (RR ± 0.5) [17]. The overall event rates in
our examples were 7.7% [13], 1.1% [14], and 1.5% [15],
respectively.
Conclusion
In summary, the exclusion of zero total event trials from
meta-analyses increases the effect size compared to meta-
analyses that include these trials. The magnitude of this
increase is relatively small for RR and OR, but more sub-
stantial if RD is used to pool the results. Zero total event
trials are currently included only if RD is used as the effect
measure. We believe these trials should also be included if
Meta-analysis investigating the use of prophylactic subcutaneous unfractionated or low-molecular weight heparin after hip frac- ture repair to prevent deep vein thrombosis [15] Figure 3
Meta-analysis investigating the use of prophylactic subcutaneous unfractionated or low-molecular weight heparin after hip frac-
ture repair to prevent deep vein thrombosis [15]. Endpoint: non-fatal pulmonary embolism (total of 8 events in 245 patients in 
the intervention group and 0 events in 292 patients in the control group). For a description of bar charts and plots see figure 
legend for Figure 1.
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RR or OR are the effect measures to provide a more con-
servative estimate of effect size (even if this change in
effect size is very small for RR and OR), and to provide
analytic consistency and include the same number of tri-
als in the meta-analysis, regardless of the summary effect
measure used. Inclusion of zero total event trials would
enable the inclusion of all available randomized control-
led trial data in a meta-analysis, thereby providing the
most generalizable estimate of treatment effect.
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